Analysis of 41 cancer cell lines reveals excessive allelic loss and novel mutations in the SIRT1 gene

Cell Cycle

Volumn 12, Issue 2, 2013, Pages 263-270

  Han, Jeehae ^a   Hubbard, Basil P ^b   Lee, Jaehoon ^c   Montagna, Cristina ^a   Lee, Han Woong ^c   Sinclair, David A ^b   Suh, Yousin ^a,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Yonsei University   (South Korea)

^d GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Allelic loss; Breast cancer; Cell line; Gene mutation; SIRT1; Tumor suppressor

Indexed keywords

HISTONE DEACETYLASE; PROTEIN P53; SIRTUIN 1; TELOMERASE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE LOCUS; GENE LOSS; GENETIC VARIABILITY; GENOMIC INSTABILITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN FUNCTION; REGULATORY MECHANISM; SEQUENCE ANALYSIS;

EID: 84873674760     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.23056     Document Type: Article

References (37)

1. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13:2570-80; PMID:10521401; http://dx.doi.org/10.1101/gad.13.19.2570.
2. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001; 410:227-30; PMID:11242085; http://dx.doi.org/10.1038/35065638.
3. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 2004; 101:15998- 6003; PMID:15520384; http://dx.doi.org/10.1073/pnas.0404184101.
4. Haigis MC, Guarente LP. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20:2913-21; PMID:17079682; http://dx.doi.org/10.1101/gad.1467506.
5. Fusco S, Maulucci G, Pani G. Sirt1: Def-eating senescence? Cell Cycle 2012; 11:4135-46; PMID:22983125; http://dx.doi.org/10.4161/cc.22074.
6. Guarente L, Franklin H. Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med 2011; 364:2235-44; PMID:21651395; http://dx.doi.org/10. 1056/NEJMra1100831.
7. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008; 7:841-53; PMID:18827827; http://dx.doi.org/10.1038/nrd2665.
8. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 2009; 5:147-52; PMID:19173036; http://dx.doi.org/10.7150/ijbs.5.147.
9. Calvanese V, Fraga MF. SirT1 brings stemness closer to cancer and aging. Aging (Albany NY) 2011; 3:162-7; PMID:21307403.
10. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67:6612-8; PMID:17638871; http://dx.doi.org/10.1158/0008-5472.CAN-07-0085.
11. Stünkel W, Peh BK, Tan YC, Nayagam VM, Wang X, Salto-Tellez M, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007; 2:1360- 8; PMID:17806102; http://dx.doi.org/10.1002/biot.200700087.
12. Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 2007; 299:103-6; PMID:17180656; http//dx.doi.org/10.1007/s00403-006-0725-6.
13. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005; 19:1751- 9; PMID:16121216; http://dx.doi.org/10.1038/sj.leu. 2403910.
14. Kriegl L, Vieth M, Kirchner T, Menssen A. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget 2012; 3:1182- 93; PMID:23045412.
15. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123:437-48; PMID:16269335; http://dx.doi.org/10.1016/j.cell.2005.08.011.
16. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454-63; PMID:18455128; http://dx.doi.org/10. 1016/j.ccr.2008.03.004.
17. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303:2011-5; PMID:14976264; http://dx.doi.org/10.1126/ science.1094637.
18. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer 2010; 10:819-23; PMID:21102633; http://dx.doi.org/10.1038/nrc2962.
19. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14:312-23; PMID:18835033; http://dx.doi.org/10.1016/j.ccr. 2008.09.001.
20. Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, Park SK, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008; 135:907- 18; PMID:19041753; http://dx.doi.org/10.1016/j.cell.2008.10.025.
21. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008; 3:e2020; PMID:18414679; http://dx.doi.org/10.1371/ journal.pone.0002020.
22. Harkes IC, Elstrodt F, Dinjens WN, Molier M, Klijn JG, Berns EM, et al. Allelotype of 28 human breast cancer cell lines and xenografts. Br J Cancer 2003; 89:2289-92; PMID:14676808; http://dx.doi.org/10.1038/sj.bjc.6601448.
23. Palacios JA, Herranz D, De Bonis ML, Velasco S, Serrano M, Blasco MA. SIRT1 contributes to telomere maintenance and augments global homologous recombination. J Cell Biol 2010; 191:1299- 313; PMID:21187328; http://dx.doi.org/10.1083/jcb.201005160.
24. Wang RH, Kim HS, Xiao C, Xu X, Gavrilova O, Deng CX. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest 2011; 121:4477-90; PMID:21965330; http://dx.doi.org/10.1172/JCI46243.
25. Fang Y, Nicholl MB. Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett 2011; 306:10-4; PMID:21414717; http://dx.doi.org/10.1016/j.canlet. 2011.02.019.
26. Li K, Luo J. The role of SIRT1 in tumorigenesis. N Am J Med Sci (Boston) 2011; 4:104-6; PMID:22180829; http://dx.doi.org/10.7156/v4i2p104.
27. Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 2008; 32:11-20; PMID:18851829; http://dx.doi.org/10.1016/j.molcel.2008.09.011.
28. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009; 284:18210- 7; PMID:19433578; http://dx.doi.org/10.1074/jbc.M109.000034.
29. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006; 66:41-5; PMID:16397213; http://dx.doi.org/10.1158/0008-5472.CAN-05-2853.
30. Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV, et al. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol 2007; 9:1253-62; PMID:17934453; http://dx.doi.org/10.1038/ncb1645.
31. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23:2369-80; PMID:15152190; http://dx.doi.org/10.1038/ sj.emboj.7600244.
32. Yuan J, Minter-Dykhouse K, Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 2009; 185:203-11; PMID:19364925; http://dx.doi.org/10.1083/jcb.200809167.
33. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, Matsuyama S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 2003; 5:320-9; PMID:12652308; http://dx.doi.org/10.1038/ncb950.
34. Narala SR, Allsopp RC, Wells TB, Zhang G, Prasad P, Coussens MJ, et al. SIRT1 acts as a nutrientsensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol Biol Cell 2008; 19:1210-9; PMID:18184747; http://dx.doi.org/10.1091/mbc.E07-09-0965.
35. Yang Y, Hubbard BP, Sinclair DA, Tong Q. Characterization of murine SIRT3 transcript variants and corresponding protein products. J Cell Biochem 2010; 111:1051-8; PMID:20677216; http://dx.doi.org/10.1002/jcb.22795.
36. Herbert BS, Hochreiter AE, Wright WE, Shay JW. Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol. Nat Protoc 2006; 1:1583-90; PMID:17406450; http://dx.doi.org/10.1038/nprot.2006.239.
37. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15:7-12; PMID:10612815; http://dx.doi.org/10.1002/(SICI)1098-1004(200001)15: 1<7::AIDHUMU4>3.0.CO;2-N.